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ABSTRACT 
Arteriovenous malformations (AVM) of the brain are considered congenital. Most AVMs are 
presumably sporadic, however rare familial cases occur and they may be observed in certain 
genetic disorders. We sought to determine the frequency of KRAS mutations and their association 
with clinicopathologic characteristics. We searched our neuropathology database from 2014-
2017 for resected AVMs of the brain or dura mater. Twenty-one AVMs were tested (12 females, 
9 males; average age: 32 years). KRAS mutations were found in 6/21 cases (28.5%). Five 
mutations were p.G12V, and one p.G12C. The KRAS-mutant group contained 4 females and 2 
males, with an average age of 28 years, compared to 34 years in the non-mutant group (p=0.54). 
The average AVM size in the KRAS-mutant group was 3.9 cm, compared to 3.1 cm in the non-
mutant group (p=0.52). There were no histologic differences between KRAS-mutant and non-
mutant cases. In summary, KRAS mutations occur in almost one third of brain AVMs. KRAS 
p.G12V was the most common mutation identified. We also demonstrate the first reported
instance of a KRAS p.G12C mutation in a brain AVM. The mean age of patients with KRAS-
mutant AVMs was lower than the non-mutant group, and the mean size larger. Histologic 
characteristics were equally distributed between KRAS-mutant and non-mutant groups. 
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Highlights 
 
- Most brain arteriovenous malformations are presumably sporadic, but rare familial cases 
have been reported. 
 
- KRAS mutations occur in almost one third of brain arteriovenous malformations (AVMs). 
 
- All observed clinical and histologic data of brain AVMs were equally distributed and 
similarly present in all AVMs, regardless of KRAS status. 
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INTRODUCTION 
Brain arteriovenous malformations (AVM) are fistulous aggregations of arterial and 
venous vessels, are considered to be congenital, and may present across a large age range [1]. 
They have an incidence of up to approximately 2 per 100,000 person-years [2], and are 
responsible for approximately 4% of intracerebral hemorrhages, including up to one-third of 
intracerebral hemorrhages in young adults [3].  Most brain AVMs are presumably sporadic, but 
rare familial cases have been reported [4] and they may be observed in genetic disorders such as 
hereditary hemorrhagic telangiectasia [5], capillary malformation-arteriovenous malformation 
syndrome [6], and Wyburn-Mason syndrome [7].  
Recently, Nikolaev et al. reported KRAS mutations in tissue from 45/72 brain AVMs 
(62.5%), but none within 21 paired blood samples [8]. In the same study, KRAS mutations were 
detected in endothelial cells from human brain AVMs in vitro and it was noted that mutant KRAS 
expression initiated increased ERK activity that was counteracted by inhibition of mitogen-
activated protein kinase (MAPK)-ERK signaling. In addition, based on immunohistochemistry of 
25 AVMs, Nikolaev et al. concluded that activation of the MAPK-ERK pathway is a defining 
molecular signature of AVMS. The initiating events for AVMs without RAS mutations are 
uncertain, however the pathogenetic mechanisms resulting from RAS-initiated activation of the 
MAPK-ERK pathway are mediated by angiogenic genes (e.g. VEGF A/C) and proteins in the 
notch signaling pathway.[9-12]  In this study, we postulated that these mechanisms may result in 
potentially distinguishable clinical and/or histologic features between KRAS-mutant and non-
mutant AVMs.   
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METHODS 
Cases 
A search of our neuropathology archives for intracranial AVMs was performed from 
2014-2017.  Hematoxylin and eosin (H&E) -stained and Verhoeff-van Gieson-stained slides 
were reviewed to confirm the diagnosis according to published texts.[13, 14] Slides were also 
examined to tissue adequacy and viability for molecular testing. Cases were excluded from 
molecular testing if the tissue amount was insufficient or if the tissue was felt to be extensively 
damaged by artifact (e.g. cautery). 
Reviews of electronic clinical records were performed for patient age, gender, presenting 
symptoms, and past medical history (with particular reference to history of additional intracranial 
or extracranial vascular lesions). Imaging studies were reviewed to document the size and 
location of the AVM nidus. Family histories were also reviewed, particularly for history of brain 
AVMs, other vascular lesions, or stroke.  
After identification of KRAS-mutant and non-mutant cases, H&E-stained and Verhoeff-
van Gieson-stained slides were reexamined for differing histology between groups. 
Immunohistochemical stains for Ki-67 (Clone MIB-1; Dako, Santa Clara, CA) were also 
performed. The principle features considered in this examination included general diagnostic 
architectural characteristics, evidence of proliferative activity (mitoses, Ki-67 labelling in 
endothelial cells and vascular smooth muscle cells), and proportion of vascular channels with 
and without elastic laminae (either partial or complete circumferential staining). This research 
was approved by the Institutional Review Board.  
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KRAS Mutational Analysis 
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved from each 
included case. KRAS mutation analysis was performed in a Clinical Laboratory Improvements 
and Amendments (CLIA) certified molecular pathology laboratory. DNA extraction from each 
block was performed using the Qiagen QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, 
USA). DNA concentration was determined using the NanoDrop Spectrophotometer and adjusted 
to approximately 10 ng/μl in ddH2O.  Polymerase chain reaction (PCR) testing was performed 
according to the recommended procedure using the Qiagen therascreen KRAS RGQ PCR Kit on 
the Qiagen Rotor-Gene Q MDx instrument.  The therascreen KRAS RGQ PCR Kit provides eight 
separate PCR amplification reactions: seven mutation-specific reactions in codons 12 and 13 of 
exon 2 of the KRAS oncogene, and a wild-type control in exon 4.  Analysis of crossing 
thresholds and mutation calls for each PCR amplification reaction were performed by the Rotor-
Gene Q therascreen KRAS Assay Package once runs were completed. 
 
Statistical Analysis 
Student’s t-tests were performed to assess for significance between patient age, gender, 
and AVM sizes in KRAS-mutant and non-mutant groups. Fisher's exact test was used to compare 
categorical data for clinicopathologic characteristics between KRAS mutated and non-mutant 
groups. Statistical significance was defined as p < 0.05 and all p values were two-tailed. 
 
RESULTS 
Twenty-one AVM resections diagnosed by our neuropathology service from 2014-2017 
were determined to be viable and sufficient for molecular testing. Slide review confirmed the 
AVM diagnosis in all cases. This 21-case cohort included material from 12 females and 9 males. 
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The average patient age was 32 years (median: 32 years; range: 9-65 years). Table 1 contains a 
summary of data from each case. 
Clinical records revealed that only one patient, an 11 year-old girl with a left frontal lobe 
AVM, had a history of an additional vascular malformation that was within the parotid gland. No 
patients had multiple intracranial AVMs. No patients had a family history of intracranial AVMs 
or extracranial vascular lesions. Only one patient had a family history of stroke, but the cause 
was not indicated. The most common presenting symptom was hemorrhage (10 cases, 48%), 
followed by headache (5 cases, 24%), seizure (4 cases, 19%), and tinnitus (1 case, 5%). In one 
case, the AVM was incidentally discovered. The AVM locations were intraparenchymal within 
the brain in 20 cases, and dural-based in 1 case. When intraparenchymal, most AVMs were 
intracerebral (frontal lobe: 8 cases, parietal lobe: 5 cases, temporal lobe: 4 cases, occipital lobe: 2 
cases). One case was cerebellar. AVM size was reported in 20/21 cases. The average AVM size 
was 3.3 cm (median: 3 cm, range: 1.7-9.0 cm). 
KRAS mutation analysis revealed mutations in 6/21 cases (28.5%). Five of the 6 mutated 
cases involved p.G12V mutations, and 1 involved a p.G12C mutation. The KRAS-mutant group 
contained 4 females and 2 males, and the average patient age was 28 years (median: 24 years, 
range: 9-65 years). Presenting symptoms for the AVMs in the KRAS-mutant group included 4 
cases with hemorrhage and 2 with headaches. All 6 of the KRAS-mutant cases were intracerebral 
(frontal lobe: 2 cases, temporal lobe: 2 cases, parietal lobe: 1 case, occipital lobe: 1 case). The 
average AVM size in the KRAS-mutant group was 3.9 cm. The non-mutant group contained 8 
females and 7 males, and the average age was 34 years (median: 34 years, range: 11-57 years).\ 
Presenting symptoms for the AVMs in the non-mutant group included 6 cases with 
hemorrhage, 4 with seizures, 3 with headaches, 1 with tinnitus, and 1 was incidentally 
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discovered. The average AVM size in the non-mutant group was 3.1 cm (n=14). There was no 
significant difference between KRAS-mutant and non-mutant groups regarding age (p=0.546), 
AVM size (p=0.522), or gender (p=0.659). The patients with the aforementioned family history 
of stroke and personal history of a vascular malformation in the parotid gland were in the non-
mutant group.  
Examination of H&E-stained slides revealed similar diagnostic histologic features 
between KRAS-mutant and non-mutant groups (Figure 1). Mitotic figures were not readily 
identified in either group. Examination of Verhoeff-van Gieson-stained slides revealed that the 
average ratio of AVM vessels containing completely or partially circumferential elastic laminae 
to those that do not was 0.42 overall (range 0.25-0.75). The average ratio for KRAS-mutant 
AVMs was 0.46 (range: 0.25-0.75), compared to 0.41 (range: 0.25-0.67) in non-mutant AVMs. 
Ki-67 immunohistochemical stains performed on sections from each case revealed labelling that 
was <1% in all cases, whether KRAS-mutant or non-mutant, in both the endothelial cells and 
smooth muscle cells of the AVM vessels (Figure 2).  
 
DISCUSSION 
Brain AVMs are a common cause of intracranial hemorrhage. In addition to clinical 
presentations relating to hemorrhage, brain AVMs can also have presentations including seizures 
or headaches, while others (at least 15%) are asymptomatic[3]. Most AVMs are presumably 
sporadic, but there are rare familial cases and AVMs also occur in a number of congenital 
syndromes[4-7]. For example, there is a 4-13% prevalence of brain AVMs in patients with 
hereditary hemorrhagic telangiectasia[15, 16]. Recently, activating KRAS mutations were noted 
in 62.5% of 72 brain AVMs, but in none of 21 paired blood samples[8]. The KRAS mutations 
reported, in order of frequency, were p.G12D, p.G12V, and p.Q61H. In this study, we 
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investigated KRAS mutations in brain AVMs and compared basic clinical and histologic 
information to assess for distinguishing features between KRAS-mutant and non-mutant AVMs. 
Of 21 brain AVM cases in our cohort, 6 (28.5%) contained KRAS mutations by PCR. We 
thus demonstrate that a subset of brain AVMs contain KRAS mutations and confirm that KRAS 
mutations should be considered amongst possible mutations in AVMs that may represent key 
genetic drivers in their development. Other mutations reported in vascular malformations include 
somatic mutations in the RAS-MAPK pathway, which have been noted in brain AVMs, and 
mutations in the PI3K pathway[17-21]. Interestingly, KRAS is mostly implicated in 
tumorigenesis and cancer, where mutations promote unregulated activation of growth-promoting 
signal transduction pathways resulting in cell transformation and genomic instability [9-12]. The 
presence of KRAS mutations in brain AVMs thus raises the question of whether they may 
represent a neoplastic process rather than a malformative one. However, though activating KRAS 
mutations are usually affiliated with malignancy, brain AVMs are not known to have malignant 
potential. Also worth noting is that there may be different roles of KRAS mutations in the 
contexts of different disease processes. For example, endometriosis is essentially not associated 
with malignancy, but about one quarter of deep infiltrating endometriotic lesions have been 
reported to harbor driver mutations associated with cancer, including KRAS mutations [22]. 
Substantially more research is necessary in order to reach an understanding of cancer-associated 
driver mutations in the setting of benign, and even potentially non-neoplastic disease processes.  
KRAS mutations in brain AVMs may also have interesting implications with regard to therapy, as 
our knowledge of RAS oncogenes and potentially targetable, RAS-associated proteins and 
processes grows and therapies are put into clinical use[23, 24].    
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The most common KRAS mutation in our cohort was p.G12V, and no cases harbored a 
p.G12D mutation. This is in contrast to a previous report that detected p.G12D as the most 
common KRAS mutation in brain AVMs, followed by p.G12V[8]. In one case, our study also 
detected a p.G12C mutation in a brain AVM, and this has not been previously reported. This 
finding is of interest considering that KRAS p.G12C mutations have been recently identified as 
potentially targetable in cancer therapy and p.G12C inhibitors are currently being 
investigated.[25-28]
 
Clinical information in our cohort revealed no distinguishing features between KRAS-
mutant and non-mutant groups. No patients had a history of multiple brain AVMs. Only one 
patient, a child with an AVM in the non-mutant group, had an additional vascular malformation 
outside of the brain. There were no documented family histories of intra- or extracranial vascular 
malformations. Presenting symptoms between the groups were similar, but none in the KRAS-
mutant group presented with seizures. The average age in the KRAS-mutant group (28 years) was 
lower than the non-mutant group (34 years), but the oldest patient in the study was in the KRAS-
mutant group, and the age difference was not statistically significant. The average AVM size was 
larger in the KRAS-mutant group (3.9 cm) than the non-mutant group (3.1 cm), but this also was 
not statistically significant. Additional studies with larger cohorts are necessary to definitively 
determine if there are substantive differences in patient age and AVM size between KRAS-
mutant and non-mutant cases. Finally, conventional histology for brain AVMs was observed in 
all cases of our study and histologic characteristics, including proportions of elastin-containing 
vessels and evidence of proliferative activity, were equally distributed and similarly present in all 
brain AVMs regardless of KRAS status. Nikolaev et al. reported that KRAS mutations in the 
endothelial cells of brain AVMs in vitro initiated activation of the MAPK-ERK pathway [8]. 
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They also concluded immunohistochemically that MAPK-ERK activation is a defining 
molecular feature of brain AVMs, with or without initiation by a KRAS mutation. Initiating 
events for AVMs without RAS mutation are uncertain.  The result of our histologic investigation 
between KRAS-mutant and non-mutant AVMs likely indicates that the histology of brain AVMs 
is not specific to activating KRAS mutations. Instead, it may indicate that the histology of brain 
AVMs is a reflection of MAPK-ERK activation in general, regardless of the initiating event.  
This suggests that the presence of KRAS mutations within AVMs may be of little clinical or 
pathologic importance. 
The frequency of KRAS mutations in brain AVMS noted in our study is lower than 
previously reported. There may be several reasons for this discrepancy. The first may be 
divergence in methodology. Our study implemented a therascreen KRAS RGQ PCR Kit, a FDA 
approved  real-time PCR assay that detects 7 mutations in codons 12 and 13 of exon 2 of the 
KRAS gene. The estimated limit of detection (analytical sensitivity) of the KRAS assay in our 
laboratory is 1%.   The original publication by Nikolaev et al. used droplet digital PCR, and 
established a minimum of 0.5% fractional abundance for a positive sample [8].  Discrepancy 
may also be due to difference in materials. Our study utilized only FFPE for real-time PCR 
testing, while the previous study utilized both FFPE and fresh frozen tissues for genetic anlaysis 
[8].  However, a large analysis of DNA quality from FFPE tissues was published by Einaga et al 
[29], and the results showed that the DNA extracted from FFPE tissue was sufficient for 
sequencing based tests.   
Tissue sampling may also have contributed to discrepancy: brain AVMs contain 
numerous cell types and, as previously reported, it is endothelial cells that contain KRAS 
mutations in brain AVMs [8]. It is possible that mutations were undetected in some cases owing 
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to undersampling of endothelial cells relative to other AVM components. Finally, there may be 
some discrepancy as a result of a potential difference in our patient population. Further studies 
would be necessary to assess the true frequency of KRAS mutations in brain AVMs, 
In conclusion, we demonstrate that approximately one third of brain AVMs harbor KRAS 
mutations that may be among key genetic drivers behind their development. KRAS p.G12V was 
the most common KRAS mutation identified in our study. We also demonstrate the first reported 
instance of a KRAS p.G12C mutation in a brain AVM.  The mean age of patients with KRAS-
mutant AVMs was slightly lower than in the non-mutant group, and the mean size larger. In this 
study, all observed histologic criteria of brain AVMs were equally distributed and similarly 
present in all AVMs, regardless of KRAS status. This indicates that the clinical features and 
histology of brain AVMs are not specific to activating KRAS mutations, and therefore that KRAS 
mutations in brain AVMS may be of little clinical or pathologic importance.  
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Figure Legends 
Figure 1. Photomicrographs of brain arteriovenous malformations (AVMs), 100x magnification. 
A-C: non-mutant AVMs, D-F: KRAS-mutant AVMs. All AVMs displayed the conventional 
histology of mixed arterial and venous channels, and 'arterialized veins' embedded in gliotic 
brain parenchyma, and were occasionally noted with hemorrhage (B,F) and inflammatory 
infiltrates (arrow) (E). KRAS-mutant and non-mutant AVMS were not distinguishable 
histologically. 
 
Figure 2. Photomicrographs of brain arteriovenous malformations (AVMs), 100x magnification. 
A-C non-mutant AVM case, D-F: KRAS-mutant AVM case. Comparison of Hematoxylin & 
Eosin (A and D), Verhoeff-van Gieson stains (B and E), and Ki-67 immunohistochemical stains 
(C and F).  Regardless of mutation status, all AVMs displayed the conventional histology of 
mixed arterial and venous channels, and 'arterialized veins', evidenced further by discontinuities 
in the elastic lamina as demonstrated by Verhoeff-van Gieson staining. Also, both KRAS-mutant 
and non-mutant AVMs all similarly displayed little to no evidence of proliferative activity via 
Ki-67 immunohistochemical staining, with stains essentially being negative in all components of 
the lesions (proliferative index of <1%). The foci of brown discoloration in photomicrograph F 
are hemosiderin deposits.    
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Table 1. Arteriovenous malformation of the brain: individual case data 
Cas
e 
Age Sex Presentation AVM 
Location 
AVM 
Side 
AVM Size 
(cm) 
 KRAS status 
1 24 Female Seizure Frontal lobe Left 4.9 Wild-type 
2 27 Female Hemorrhage Frontal lobe Left 3.0 Wild-type 
3 38 Male Hemorrhage Temporal lobe Left 5.7 Wild-type 
4 9 Female Hemorrhage Temporal lobe Left 3.5 G12V 
5 65 Male Hemorrhage Parietal lobe Right 9.0 G12V 
6 54 Female Hemorrhage Temporal lobe Right 3.5 Wild-type 
7 30 Female Headache Frontal lobe Left 3.0 G12V 
8 57 Male Hemorrhage Frontal lobe Left 2.5 Wild-type 
9 34 Male Incidental Parietal lobe Right 1.7 Wild-type 
10 13 Female Hemorrhage Frontal lobe Right 4.1 G12V 
11 32 Female Hemorrhage Occipital lobe Left 2.0 G12C 
12 18 Male Headache Parietal lobe Right 1.7 G12V 
13 55 Female Seizure Temporal lobe Right 2.3 Wild-type 
14 34 Male Headache Frontal lobe Left 2.5 Wild-type 
15 20 Female Hemorrhage Cerebellum Midline 3.0 Wild-type 
16 16 Female Headache Parietal lobe Left 4.4 Wild-type 
17 18 Male Hemorrhage Occipital lobe Right 2.6 Wild-type 
18 40 Male Seizure Frontal lobe Left 2.5 Wild-type 
19 11 Female Headache Frontal lobe Left 2.0 Wild-type 
20 40 Female Seizure Parietal lobe Left 3.0 Wild-type 
21 36 Male Tinnitus Dura Midline Not listed Wild-type 
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Highlights 
 
- Most brain arteriovenous malformations are presumably sporadic, but rare familial cases 
have been reported. 
 
- KRAS mutations occur in almost one third of brain arteriovenous malformations (AVMs). 
 
- All observed clinical and histologic data of brain AVMs were equally distributed and 
similarly present in all AVMs, regardless of KRAS status. 
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